Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine for Depression in Advanced NSCLC
NCT02650544Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Mirtazapine with Placebo (2 arms). Primary endpoint: Anti-depression efficacy (response rate). Status: unknown.
02
Drugs
mirtazapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02650544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650544.